We are live on ! Find out more
ACHL

Achilles Therapeutics
ACHL

Delisted

ACHL was delisted on the 20th of March, 2025.

Back to rankings

Fund managers haven’t disclosed any holdings of ACHL yet.

ACHL Hedge Fund Activity: Q1 2026 in Review

3 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q1 2026, worth a combined $53.3K — up 582% from $7.82K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new ACHL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Trium Capital, opening a new position worth an estimated $45.5K.

  • 3 institutional investors held Achilles Therapeutics (ACHL) as of Q1 2026, up from 2 in Q4 2025.
  • Funds reported $53.3K of Achilles Therapeutics stock for Q1 2026, up 582% quarter-over-quarter.
  • 1 fund opened new Achilles Therapeutics positions in Q1 2026 and 0 closed out, a net change of +1 holder.
  • The largest Achilles Therapeutics buyer in Q1 2026 was Trium Capital, an estimated $45.5K added.

Based on aggregated 13F filings for Q1 2026.